Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus
New York, Jan 22, 2026, 10:14 EST — Regular session Abbott Laboratories shares dropped 7.4%, hitting $111.74 in morning trading after falling as low as $106.13. The slide came on the back of a quarterly revenue miss and a cautious outlook on near-term profits. The decline is significant because it brings back a familiar challenge for Abbott: stabilizing nutrition and preventing diagnostics from sliding as COVID-era testing wanes, all while relying on rapidly growing devices. The stock’s movement often hinges on that balance, not just on headline earnings. This comes at a tricky time for the sector. Infant formula has